APC is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains APC status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARAF is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 3 clinical trials for diffuse glioma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and diffuse glioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYB is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYBL1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYBL1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCL is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

OTX2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTPN1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTPN1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RELA is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains RELA status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SHH status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SOS1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SUFU is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TERT is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains TERT status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

YAP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].